Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Most Cited Paper
in Immunotherapy and Immune Responses
18 Months Post-Publication
Class of 2026
“Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/
Topics
ELI-002 2P · amphiphile modification · KRAS G12D mutation · KRAS G12R mutation · Amph-Peptides-2P · Amph-CpG-7909 · lymph node delivery · Minimal residual disease (MRD) · ctDNA · serum tumor antigen · mKRAS-specific T cell responses · CD4+ T cells · CD8+ T cells · tumor biomarker clearance · relapse-free survival · ex vivo T cell assay · CpG oligonucleotide adjuvant · phase 1 dose escalation · recommended phase 2 dose
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459